


Serial No.: 08/167,846  
Group Art Unit No.: 1201

Please add new claims 29-51, as follows:

~~29.~~ A method of treatment of a condition wherein a 5-HT<sub>1</sub>-like agonist is indicated, which comprises administering to a subject in need thereof an effective amount of a compound of general formula (I):



Formula (I)

wherein :

R<sup>1</sup> represents -(CH<sub>2</sub>)<sub>n</sub>CONR<sup>5</sup>R<sup>6</sup>;

R<sup>5</sup> and R<sup>6</sup> each independently represent hydrogen, methyl, ethyl or propyl;

n represents 0; and

R<sup>2</sup> and R<sup>3</sup> each independently represent hydrogen, methyl or ethyl;  
or a physiologically acceptable salt thereof.


~~29.~~ The method according to claim ~~29~~ wherein the condition is migraine.

~~30.~~ The method according to claim ~~29~~ wherein the condition is cluster headache.

~~31.~~ The method according to claim ~~29~~ wherein the condition is headache associated with vascular disorders.

~~32.~~ A compound of general formula (I):

Serial No.: 08/167,846  
Group Art Unit No.: 1201



wherein:

R<sup>1</sup> represents -(CH<sub>2</sub>)<sub>n</sub>CONR<sup>5</sup>R<sup>6</sup>;

R<sup>5</sup> and R<sup>6</sup> each independently represent hydrogen, methyl, ethyl or propyl;

n represents 0; and

R<sup>2</sup> and R<sup>3</sup> each independently represent hydrogen, methyl or ethyl;

or a physiologically acceptable salt thereof.

*34.* The compound of claim 33 wherein R<sup>5</sup> and R<sup>6</sup> are hydrogen or methyl.

*35.* The compound as claimed in claim 35, wherein:

R<sup>1</sup> represents -(CH<sub>2</sub>)<sub>n</sub>CONR<sup>5</sup>R<sup>6</sup>;

R<sup>5</sup> and R<sup>6</sup> are each hydrogen;

n represents 0; and

R<sup>2</sup> is hydrogen and R<sup>3</sup> is methyl;

or a physiologically acceptable salt thereof.

*36.* A pharmaceutical composition comprising a compound of formula (I) according to claim 33 or a physiologically acceptable salt thereof and a physiologically acceptable carrier.

*37.* A method of treatment of a condition wherein a 5-HT<sub>1</sub>-like agonist is indicated, which comprises administering to a subject in need thereof an effective amount of a compound of claim 33.

*38.* The method according to claim 37 wherein the condition is migraine.

*39.* The method according to claim 37 wherein the condition is cluster headache.

Serial No.: 08/167,846  
Group Art Unit No.: 1201

~~12~~ 40. The method according to claim ~~37~~ wherein the condition is headache associated with vascular disorders.

~~13~~ 41. A pharmaceutical composition comprising a compound of formula (I) according to claim ~~35~~, or a physiologically acceptable salt thereof and a physiologically acceptable carrier.

~~14~~ 42. A compound of formula (I) which is (+)-3-amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole, or a salt, solvate or hydrate thereof.

~~15~~ 43. A compound of formula (I) which is (-)-3-amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole, or a salt, solvate or hydrate thereof.

~~16~~ 44. A compound of formula (I) which is 3-methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole, or a salt, solvate or hydrate thereof.

~~17~~ 45. A compound of formula (I) which is 3-ethylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole, or a salt, solvate or hydrate thereof.

~~18~~ 46. A compound of formula (I) which is 3-dimethylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole, or a salt, solvate or hydrate thereof.

~~2~~ 47. A method of treatment of a condition wherein a 5-HT<sub>1</sub>-like agonist is indicated, which comprises administering to a subject in need thereof an effective amount of a compound of claim ~~44~~.

~~3~~ 48. The method according to claim ~~44~~ wherein the condition is migraine.

~~4~~ 49. The method according to claim ~~44~~ wherein the condition is cluster headache.

~~5~~ 50. The method according to claim ~~44~~ wherein the condition is headache associated with vascular disorders.

40